Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer & rsquo;s Perspective
Source: ClinicoEconomics and Outcomes Research - Category: Health Management Tags: ClinicoEconomics and Outcomes Research Source Type: research
More News: Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Health Management | India Health